APRE Stock: Why It Increased Today

By Amit Chowdhry ● Sep 20, 2021
  • The stock price of Aprea Therapeutics Inc (NASDAQ: APRE) is trading higher today. This is why it happened.

The stock price of Aprea Therapeutics Inc (NASDAQ: APRE) – a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein p53 – is trading higher today. Investors are citing the company’s upcoming mini oral presentation. The presentation is about data for eprenetapopt in combination with pembrolizumab for the treatment of advanced solid tumors.

The data for the presentation lined up for the European Society of Medical Oncology (ESMO) Congress 2021 on Sept. 20 at 11:35 – 11:40 am EDT. And it is titled “Phase I/II study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with solid tumor malignancies.”

About a month ago, the FDA placed a clinical hold on the company’s clinical trial evaluating eprenetapopt with acalabrutinib or with venetoclax and rituximab in lymphoid malignancies. And no additional patients can be enrolled until the clinical hold is resolved. But the patients on study deriving clinical benefit could continue to receive study treatment.

Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.